Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Magnetic-Resonance-Imaging Texture Analysis Predicts Early Progression in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiation.
Nardone V, Reginelli A, Scala F, Carbone SF, Mazzei MA, Sebaste L, Carfagno T, Battaglia G, Pastina P, Correale P, Tini P, Pellino G, Cappabianca S, Pirtoli L. Nardone V, et al. Among authors: correale p. Gastroenterol Res Pract. 2019 Jan 17;2019:8505798. doi: 10.1155/2019/8505798. eCollection 2019. Gastroenterol Res Pract. 2019. PMID: 30847005 Free PMC article.
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.
Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, Rotundo MS, Tassone P, Sperlongano P, Abbruzzese A, Caraglia M, Tagliaferri P, Francini G. Correale P, et al. Cancer Biol Ther. 2010 May 1;9(9):685-93. doi: 10.4161/cbt.9.9.11441. Cancer Biol Ther. 2010. PMID: 20697196 Free article. Clinical Trial.
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.
Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I, Guglielmo A, Pirtoli L, Sperlongano P, Gridelli C, Caraglia M, Tassone P, Tagliaferri P, Correale P. Botta C, et al. Among authors: correale p. Cancer Biol Ther. 2013 Jun;14(6):469-75. doi: 10.4161/cbt.24425. Cancer Biol Ther. 2013. PMID: 23760488 Free PMC article.
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial.
Correale P, Botta C, Rotundo MS, Guglielmo A, Conca R, Licchetta A, Pastina P, Bestoso E, Ciliberto D, Cusi MG, Fioravanti A, Guidelli GM, Bianco MT, Misso G, Martino E, Caraglia M, Tassone P, Mini E, Mantovani G, Ridolfi R, Pirtoli L, Tagliaferri P. Correale P, et al. J Immunother. 2014 Jan;37(1):26-35. doi: 10.1097/CJI.0000000000000004. J Immunother. 2014. PMID: 24316553 Clinical Trial.
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients.
Cusi MG, Botta C, Pastina P, Rossetti MG, Dreassi E, Guidelli GM, Fioravanti A, Martino EC, Gandolfo C, Pagliuchi M, Basile A, Carbone SF, Ricci V, Micheli L, Tassone P, Tagliaferri P, Pirtoli L, Correale P. Cusi MG, et al. Among authors: correale p. Cancer Immunol Immunother. 2015 Sep;64(9):1159-73. doi: 10.1007/s00262-015-1711-7. Epub 2015 Jun 2. Cancer Immunol Immunother. 2015. PMID: 26031574 Free PMC article. Clinical Trial.
Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.
Correale P, Botta C, Martino EC, Ulivieri C, Battaglia G, Carfagno T, Rossetti MG, Fioravanti A, Guidelli GM, Cheleschi S, Gandolfo C, Carbone F, Baldari TC, Tassone P, Tagliaferri P, Pirtoli L, Cusi MG. Correale P, et al. Oncoimmunology. 2015 Dec 21;5(4):e1101205. doi: 10.1080/2162402X.2015.1101205. eCollection 2016 Apr. Oncoimmunology. 2015. PMID: 27141384 Free PMC article.
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.
Martino EC, Misso G, Pastina P, Costantini S, Vanni F, Gandolfo C, Botta C, Capone F, Lombardi A, Pirtoli L, Tassone P, Ulivieri C, Tagliaferri P, Cusi MG, Caraglia M, Correale P. Martino EC, et al. Among authors: correale p. Cell Death Discov. 2016 Oct 3;2:16025. doi: 10.1038/cddiscovery.2016.25. eCollection 2016. Cell Death Discov. 2016. PMID: 27752361 Free PMC article.
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse.
Nardone V, Botta C, Caraglia M, Martino EC, Ambrosio MR, Carfagno T, Tini P, Semeraro L, Misso G, Grimaldi A, Boccellino M, Facchini G, Berretta M, Vischi G, Rocca BJ, Barone A, Tassone P, Tagliaferri P, Del Vecchio MT, Pirtoli L, Correale P. Nardone V, et al. Among authors: correale p. Cancer Biol Ther. 2016 Nov;17(11):1213-1220. doi: 10.1080/15384047.2016.1235666. Cancer Biol Ther. 2016. PMID: 27791459 Free PMC article.
Immunotherapy of colorectal cancer: new perspectives after a long path.
Correale P, Botta C, Ciliberto D, Pastina P, Ingargiola R, Zappavigna S, Tassone P, Pirtoli L, Caraglia M, Tagliaferri P. Correale P, et al. Immunotherapy. 2016 Nov;8(11):1281-1292. doi: 10.2217/imt-2016-0089. Immunotherapy. 2016. PMID: 27993089 Review.
169 results